登录 查看组织和合同定价。
选择尺寸
关于此项目
经验公式(希尔记法):
C11H12ClNO3S2
化学文摘社编号:
分子量:
305.80
NACRES:
NA.77
PubChem Substance ID:
UNSPSC Code:
12352203
MDL number:
InChI
1S/C11H11NO3S2.ClH/c13-8-2-1-7(5-9(8)14)10(15)6-17-11-12-3-4-16-11;/h1-2,5,13-14H,3-4,6H2;1H
SMILES string
Cl.Oc1ccc(cc1O)C(=O)CSC2=NCCS2
InChI key
ZZAVDVMJZKDBIB-UHFFFAOYSA-N
assay
≥98% (HPLC)
form
solid
color
white
solubility
DMSO: >20 mg/mL
storage temp.
2-8°C
Biochem/physiol Actions
RETRA is a mutant p53-dependent activator of p73, an activator of p53-regulated genes, and a suppressor of mutant p53-bearing tumor cells.
RETRA is a mutant p53-dependent activator of p73, an activator of p53-regulated genes, and a suppressor of mutant p53-bearing tumor cells. Greater than 50% of tumors express mutant p53 which is defective for the tumor-suppressor function and contributes to malignancy by blocking a p53 family member p73. Activation of p73 in human cancer produces a cytotoxic effect. RETRA increases expression level of p73 and releases p73 from the inhibitory complex with mutant 53. It thereby produces tumor-supressor effect, in vitro and in vivo, similar to functional reactivation of p53.
signalword
Danger
hcodes
pcodes
Hazard Classifications
Acute Tox. 3 Oral
存储类别
6.1D - Non-combustible acute toxic Cat.3 / toxic hazardous materials or hazardous materials causing chronic effects
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
Eyeshields, Faceshields, Gloves, type P2 (EN 143) respirator cartridges
法规信息
新产品
此项目有
Jürgen Sonnemann et al.
European journal of cancer (Oxford, England : 1990), 51(7), 841-851 (2015-03-25)
Mutant p53 can exert oncogenic activity by inhibitory interaction with p73. The small-molecule RETRA has been described to disrupt this interaction and to suppress carcinoma cells (Kravchenko et al., 2008). RETRA's anticancer activity was restricted to tumour cells bearing mutant
我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持